These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 18983511)

  • 1. Risk stratification for inhibitor development at first treatment for severe hemophilia A: a tool for clinical practice.
    ter Avest PC; Fischer K; Mancuso ME; Santagostino E; Yuste VJ; van den Berg HM; van der Bom JG;
    J Thromb Haemost; 2008 Dec; 6(12):2048-54. PubMed ID: 18983511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-A2 and anti-A1 domain antibodies are potential predictors of immune tolerance induction outcome in children with hemophilia A.
    Lapalud P; Rothschild C; Mathieu-Dupas E; Balicchi J; Gruel Y; Laune D; Molina F; Schved JF; Granier C; Lavigne-Lissalde G
    J Thromb Haemost; 2015 Apr; 13(4):540-7. PubMed ID: 25603934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors for antibody formation in children with hemophilia: methodological aspects and clinical characteristics of the HEMFIL cohort study.
    Jardim LL; Santana MP; Chaves DG; van der Bom J; Rezende SM
    Blood Coagul Fibrinolysis; 2021 Oct; 32(7):443-450. PubMed ID: 34127617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human recombinant DNA-derived antihemophilic factor in the treatment of previously untreated patients with hemophilia A: final report on a hallmark clinical investigation.
    Lusher J; Abildgaard C; Arkin S; Mannucci PM; Zimmermann R; Schwartz L; Hurst D
    J Thromb Haemost; 2004 Apr; 2(4):574-83. PubMed ID: 15102011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in The Netherlands. Dutch Hemophilia Study Group.
    Rosendaal FR; Nieuwenhuis HK; van den Berg HM; Heijboer H; Mauser-Bunschoten EP; van der Meer J; Smit C; Strengers PF; Briët E
    Blood; 1993 Apr; 81(8):2180-6. PubMed ID: 8471777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intensity of factor VIII treatment and the development of inhibitors in non-severe hemophilia A patients: results of the INSIGHT case-control study.
    van Velzen AS; Eckhardt CL; Peters M; Leebeek FWG; Escuriola-Ettingshausen C; Hermans C; Keenan R; Astermark J; Male C; Peerlinck K; le Cessie S; van der Bom JG; Fijnvandraat K
    J Thromb Haemost; 2017 Jul; 15(7):1422-1429. PubMed ID: 28440011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factor VIII products and inhibitor development in previously treated patients with severe or moderately severe hemophilia A: a systematic review.
    Hassan S; Cannavò A; Gouw SC; Rosendaal FR; van der Bom JG
    J Thromb Haemost; 2018 Jun; 16(6):1055-1068. PubMed ID: 29665204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved prediction of inhibitor development in previously untreated patients with severe haemophilia A.
    Hashemi SM; Fischer K; Moons KGM; van den Berg HM
    Haemophilia; 2015 Mar; 21(2):227-233. PubMed ID: 25495680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe hemophilia A.
    Gouw SC; van den Berg HM; le Cessie S; van der Bom JG
    J Thromb Haemost; 2007 Jul; 5(7):1383-90. PubMed ID: 17456190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab as first-line treatment for the management of adult patients with non-severe hemophilia A and inhibitors.
    Lim MY; Nielsen B; Lee K; Kasthuri RS; Key NS; Ma AD
    J Thromb Haemost; 2014 Jun; 12(6):897-901. PubMed ID: 24702722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A.
    Sharathkumar A; Lillicrap D; Blanchette VS; Kern M; Leggo J; Stain AM; Brooker L; Carcao MD
    J Thromb Haemost; 2003 Jun; 1(6):1228-36. PubMed ID: 12871324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factor VIII products and inhibitor development in severe hemophilia A.
    Gouw SC; van der Bom JG; Ljung R; Escuriola C; Cid AR; Claeyssens-Donadel S; van Geet C; Kenet G; Mäkipernaa A; Molinari AC; Muntean W; Kobelt R; Rivard G; Santagostino E; Thomas A; van den Berg HM;
    N Engl J Med; 2013 Jan; 368(3):231-9. PubMed ID: 23323899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitor development and mortality in non-severe hemophilia A.
    Eckhardt CL; Loomans JI; van Velzen AS; Peters M; Mauser-Bunschoten EP; Schwaab R; Mazzucconi MG; Tagliaferri A; Siegmund B; Reitter-Pfoertner SE; van der Bom JG; Fijnvandraat K;
    J Thromb Haemost; 2015 Jul; 13(7):1217-25. PubMed ID: 25912309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic and prognostic value of factor VIII binding antibodies in acquired hemophilia A: data from the GTH-AH 01/2010 study.
    Werwitzke S; Geisen U; Nowak-Göttl U; Eichler H; Stephan B; Scholz U; Holstein K; Klamroth R; Knöbl P; Huth-Kühne A; Bomke B; Tiede A
    J Thromb Haemost; 2016 May; 14(5):940-7. PubMed ID: 26988717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Age at first treatment and immune tolerance to factor VIII in severe hemophilia.
    van der Bom JG; Mauser-Bunschoten EP; Fischer K; van den Berg HM
    Thromb Haemost; 2003 Mar; 89(3):475-9. PubMed ID: 12624630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of factor VIII inhibitor development in the SIPPET cohort by mutational analysis and factor VIII antigen measurement.
    Spena S; Garagiola I; Cannavò A; Mortarino M; Mannucci PM; Rosendaal FR; Peyvandi F;
    J Thromb Haemost; 2018 Apr; 16(4):778-790. PubMed ID: 29399993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analyses of the FranceCoag cohort support differences in immunogenicity among one plasma-derived and two recombinant factor VIII brands in boys with severe hemophilia A.
    Calvez T; Chambost H; d'Oiron R; Dalibard V; Demiguel V; Doncarli A; Gruel Y; Huguenin Y; Lutz P; Rothschild C; Vinciguerra C; Goudemand J;
    Haematologica; 2018 Jan; 103(1):179-189. PubMed ID: 29025913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The multifactorial etiology of inhibitor development in hemophilia: genetics and environment.
    Gouw SC; van den Berg HM
    Semin Thromb Hemost; 2009 Nov; 35(8):723-34. PubMed ID: 20169509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study.
    Gouw SC; van der Bom JG; Auerswald G; Ettinghausen CE; Tedgård U; van den Berg HM
    Blood; 2007 Jun; 109(11):4693-7. PubMed ID: 17218379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitor antibodies to factor VIII and factor IX: management.
    Lusher JM
    Semin Thromb Hemost; 2000; 26(2):179-88. PubMed ID: 10919411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.